>> results from dyax phase 2 showed no change in lung function <<
LOL, no wonder DYAX did not mention lung function in yesterday’s PR. Nevertheless, the granting of orphan status makes DYAX’s drug a matter of consequence for GENR’s CF program.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”